INTRODUCTION: We analyzed the trends of positive surgical margin (PSM) location in patients that had pT3 disease at robotic assisted radical prostatectomy (RARP).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
We aimed to describe our changing incidence of positive surgical margins in the largest series to date of patients with pT3 disease treated by RARP.
METHODS: A single-institution, single-surgeon review was done of all patients who underwent RARP from 2005 to 2011. Perioperative data was collected for all patients with pT3 prostate cancer from a prospectively maintained RARP database. The PSM incidence and rates were stratified by location. The PSM rates per location were trended over time.
RESULTS: In total, 2,478 consecutive patients underwent RARP between July 2005 and December 2011. Of these patients, 555 were found to have pT3 disease. The PSM rate for patients with pT3 disease was 47%. The PSM rate for patients with pT3A and pT3B disease was 42.8% and 60.6%, respectively. Over the duration of this study the PSM rate in patients with pT3 disease decreased significantly from 70.6% in 2005 to 32.3% in 2011 (p=0.002). The apical PSM rate showed the greatest decrease during this time period going from 52.9% in 2005 to 5.2% in 2011 (p=0.018).
CONCLUSION: We present the largest series to date involving the treatment of locally advanced prostate cancer initially treated with RARP. Our findings suggest that locally advanced prostate cancer can be treated with RARP with acceptable positive margin rates. Overall PSM rates improved nearly 40% over the 6.5 year period of this study.
Lightfoot AJ, Su YK, Sehgal SS, Lee Z, Greaves GH, Yu SJ, Llukani E, Su YC, Lee D. Are you the author?
University of Pennsylvania, Urology, Philadelphia, Pennsylvania, United States.
Reference: J Endourol. 2014 Oct 30. Epub ahead of print.